子宫内膜癌患者血清血管内皮生长因子、鳞状细胞癌抗原表达水平及其与病理参数的相关性分析

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (513 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the serum levels of vascular endothelial growth factor (VEGF) and squamous cell carcinoma antigen (SCCAg) in patients with endometrial cancer and their correlation with pathological parameters. Methods Eighty cases of endometrial carcinoma treated in the Department of Obstetrics and Gynecology of Huangshan People’s Hospital of Anhui Province (hereinafter referred to as “our hospital”) from January 2017 to March 2021 were selected as the observation group, and 75 healthy women in the outpatient department of our hospital during the same period were selected as the control group. The levels of VEGF and SCCAg were compared between the two groups, and the differences of serum VEGF and SCCAg in patients with endometrial cancer with different characteristics were compared. Pearson correlation coefficient was used to analyze the correlation between VEGF and SCCAg expression levels and pathological parameters. Results The levels of VEGF and SCCAg in the observation group were higher than those in the control group, the differences were statistically significant (P ＜ 0.05). There were statistically significant differences in VEGF and SCCAg expression levels in patients with different degrees of differentiation, TNM stage, and situation of lymph node metastasis (P ＜ 0.05). Correlation analysis showed that serum VEGF and SCCAg levels were negatively correlated with the differentiation degree of endometrial carcinoma (r ＜ 0, P ＜ 0.05), and positively correlated with TNM stage and lymph node metastasis (r ＞ 0, P ＜ 0.05). Conclusion In patients with endometrial cancer, serum VEGF and SCCAg are significantly overexpressed, and their levels can provide important reference for the diagnosis and treatment of endometrial cancer.

Key words： Endometrial cancer Lymph node metastasis Vascular endothelial growth factor Squamous cell carcinoma antigen Pathological parameters Correlation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SUN Yanhong YANG Chunling WU Wei

Cite this article:

SUN Yanhong YANG Chunling WU Wei. Analysis of serum vascular endothelial growth factor and squamous cell carcinoma antigen expression levels and their correlation with pathological parameters in patients with endometrial carcinoma[J]. 中国医药导报, 2022, 19(14): 117-120.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I14/117

[1] 赫淑倩，成玉霞，綦黄鹏，等.子宫内膜癌198例临床病理特征及预后影响因素分析[J].中华肿瘤防治杂志，2019， 26（20）：1562-1568.
[2] 郭聪敏，戴一博，耿京，等.子宫内膜癌初始病灶大小与淋巴结转移及复发的关系[J].中华妇产科杂志，2021，56（4）：264-270.
[3] 陈红敏，罗艳林，高玲，等.血清糖类抗原125与血管内皮生长因子联合检测对子宫内膜癌的诊断价值及临床意义[J].癌症进展，2019，17（6）：722-726.
[4] 赵健，高坚荣.检测CA199、VEGF、HE4预测子宫内膜癌淋巴结转移价值[J].中国计划生育学杂志，2020，28（11）：1901-1904，1908.
[5] 朱成功，姜继勇，张文清，等.术前血清鳞状细胞癌抗原水平对早期宫颈鳞癌淋巴结转移的预测价值[J].现代妇产科进展，2020，29（12）：896-900.
[6] 刘梦君，李玉芝，王丽华，等.鳞状细胞癌抗原检测联合磁共振成像对判断早期宫颈癌盆腔淋巴结转移的临床意义[J].中国癌症杂志，2019，29（2）：136-141.
[7] 中华医学会病理学分会女性生殖疾病学组.子宫内膜癌病理诊断规范[J].中华病理学杂志，2020，49（3）：214-219.
[8] 中国抗癌协会妇科肿瘤专业委员会.子宫内膜癌诊断与治疗指南（2021年版）[J].中国癌症杂志，2021，31（6）：501-512.
[9] 卢婉婷，严思悠，胡志坚，等.子宫内膜癌深肌层浸润相关因素分析及预测[J].实用妇产科杂志，2019，35（6）：459-462.
[10] 高艳华，郭战坤，魏杏茹，等.191例子宫内膜癌患者淋巴结转移的相关因素分析[J].中国医师杂志，2021，23（7）：1062-1066.
[11] Son J，Carr C，Yao M，et al. Endometrial cancer in young women：prognostic factors and treatment outcomes in women aged 40 years [J]. Int J Gynecol Cancer，2020，30（5）：631-639.
[12] Ignatov A，Ivros S，Bozukova M，et al. Systematic lymphadenectomy in early stage endometrial cancer [J]. Arch Gynecol Obstet，2020，302（1）：231-239.
[13] 王成艳.子宫内膜癌组织学分型和淋巴脉管间隙浸润的多模态MR成像研究进展[J].临床放射学杂志，2020， 39（9）：1885-1889.
[14] Skok K，Maver U，Gradi?觢nik L，et al. Endometrial cancer and its cell lines [J]. Mol Biol Rep，2020，47（2）：1399-1411.
[15] 李状，李力.子宫内膜癌淋巴结转移相关基因的生物信息学分析[J].中国肿瘤生物治疗杂志，2019，26（11）：1262-1269.
[16] 季瑞，陆云燕.子宫内膜癌临床病理特征与盆腹腔淋巴结转移的相关性分析[J].现代肿瘤医学，2019，27（19）：3491-3494.
[17] Liu MC，Gardner AB，Wolford JE，et al. Endometrial cancer in the morbidly obese：a review [J]. Curr Opin Obstet Gynecol，2020，32（1）：42-50.
[18] 刘丹萍，曾友玲，梅凡.子宫内膜癌淋巴结转移的危险因素及预后分析[J].癌症进展，2019，17（3）：348-350.
[19] 张品，岳志红，刘云鹤，等.子宫内膜癌腹膜后淋巴结转移的危险因素及对预后的影响[J].癌症进展，2020，18（2）：198-201.
[20] 陈红敏，罗艳林，高玲，等.血清糖类抗原125与血管内皮生长因子联合检测对子宫内膜癌的诊断价值及临床意义[J].癌症进展，2019，17（6）：722-726.
[21] 许朝阳，陈建云.子宫内膜ER、PR、P53、VEGF表达及其与病理特征的相关性分析[J].中国妇幼保健，2019， 34（21）：5038-5041.
[22] 孙亚妮，雷静，马文娟.鳞状细胞癌抗原及肝细胞生长因子受体检测对宫颈癌淋巴结转移和预后的评估价值[J].癌症进展，2020，18（22）：2323-2326.
[23] 张雨馨，吴诗妍，楼寒梅.血清鳞状细胞癌抗原在宫颈鳞状细胞癌临床管理中的进展[J].肿瘤学杂志，2020， 26（4）：346-349.
[24] 闫丽娜，杨滢，丁建龙，等.新辅助化疗对子宫内膜癌患者血清VEGF及MMP-9的影响[J].北华大学学报（自然科学版），2019，20（1）：82-85.
[25] 喻茂文，鄢骑兵，陈建军，等.血清CA125、CA19-9、CA724、SCCAg联合检测在子宫内膜癌中的诊断价值[J].癌症进展，2019，17（17）：2074-2078，2104.